Triptodur Kit
(Triptorelin pamoate)Phase 3Small molecule
Triptodur Kit is one of 8 small molecule programs targeting Hematopoietic and Lymphatic System Neoplasm. It is currently in Phase 3.
1
Indications
12
Total Trials
1
Active Trials
7
Competitors
4
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Hematopoietic and Lymphatic System Neoplasm
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 2
Trexall
Jazz PharmaceuticalsPhase 2
Retevmo
Eli LillyPhase 2
Veklury
GileadPhase 2
Triptodur Kit
VVerity Pharmaceuticals Inc.
Phase 3
Therapeutic Hydrocortisone
EEastern Cooperative Oncology Group
Phase 2
Psilocybine
UUniversity of Zurich
Phase 2
Single Agent Therapy
TTheodore Brasky PhD
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer2 trials
Central precocious puberty2 trials
Precocious Puberty1 trial
Lupus1 trial
Triptorelin for Ovary Protection in Childhood Onset Lupus
Completed·—·Phase 2·NCT00124514·31 enrolled
5 more indications
Biochemical Recurrence1 trial
Breast Cancer1 trial
Hematopoietic and Lymphatic System Neoplasm1 trial
Prostate Adenocarcinoma1 trial
Regulatory
FDA Approval Timeline[4]
Jun 15, 2000
TRELSTAR
NDA NDA020715
Jun 29, 2001
TRELSTAR
NDA NDA021288
Mar 10, 2010
TRELSTAR
NDA NDA022437
Jun 29, 2017
TRIPTODUR KIT
NDA NDA208956
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Triptorelin pamoate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- VVerity Pharmaceuticals Inc.